全文获取类型
收费全文 | 739篇 |
免费 | 69篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 30篇 |
妇产科学 | 8篇 |
基础医学 | 125篇 |
口腔科学 | 11篇 |
临床医学 | 71篇 |
内科学 | 198篇 |
皮肤病学 | 14篇 |
神经病学 | 22篇 |
特种医学 | 156篇 |
外科学 | 50篇 |
综合类 | 39篇 |
预防医学 | 12篇 |
眼科学 | 4篇 |
药学 | 49篇 |
中国医学 | 6篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 7篇 |
2021年 | 6篇 |
2019年 | 8篇 |
2018年 | 7篇 |
2016年 | 22篇 |
2015年 | 47篇 |
2014年 | 19篇 |
2013年 | 20篇 |
2012年 | 23篇 |
2011年 | 23篇 |
2010年 | 31篇 |
2009年 | 34篇 |
2008年 | 24篇 |
2007年 | 15篇 |
2006年 | 21篇 |
2005年 | 25篇 |
2004年 | 12篇 |
2003年 | 16篇 |
2002年 | 9篇 |
2001年 | 13篇 |
2000年 | 8篇 |
1999年 | 14篇 |
1998年 | 23篇 |
1997年 | 45篇 |
1996年 | 33篇 |
1995年 | 30篇 |
1994年 | 24篇 |
1993年 | 22篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1990年 | 16篇 |
1989年 | 25篇 |
1988年 | 16篇 |
1987年 | 11篇 |
1986年 | 19篇 |
1985年 | 8篇 |
1984年 | 10篇 |
1983年 | 11篇 |
1982年 | 11篇 |
1981年 | 10篇 |
1980年 | 13篇 |
1979年 | 4篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 4篇 |
1972年 | 5篇 |
1970年 | 5篇 |
1968年 | 7篇 |
1966年 | 2篇 |
排序方式: 共有818条查询结果,搜索用时 15 毫秒
81.
82.
目的 应用网络药理学分析金藤清痹颗粒治疗急性痛风性关节炎(acute gouty arthritis,AGA)的作用机制,并建立AGA大鼠模型进行验证。方法 在清热解毒、活血止痛治法指导下,通过TCMSP数据库搜集金藤清痹颗粒的活性成分及靶点,利用GeneCards、NCBI数据库等搜集AGA相关靶点,与金藤清痹颗粒作用靶点整合后,构建共有靶点蛋白质-蛋白质相互作用(protein-protein interaction,PPI)网络和“金藤清痹颗粒-中药-活性成分-靶点-AGA”网络,并进行基因本体(gene ontology,GO)功能及京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)通路富集分析。雄性SD大鼠随机分为空白组、模型组、秋水仙碱(0.3 mg/kg)组和金藤清痹颗粒低、中、高剂量(1.05、2.10、4.20 g/kg)组,每组6只,踝关节注射单钠尿酸盐(monosodium urate,MSU)晶体建立AGA大鼠模型。采用游标卡尺测量大鼠踝关节直径,计算踝关节肿胀度;采用全自动生化仪检测血清尿酸(serum uric acid,SUA)、C反应蛋白(C-reactive protein,CRP)水平;采用苏木素-伊红(HE)染色观察踝关节组织病理变化;采用qRT-PCR、ELISA和Western blotting检测踝关节组织及血清中关键靶点和信号通路的表达。结果 共检索到金藤清痹颗粒110种活性成分、212个作用靶点,272个AGA治疗靶点,共有靶点29个,关键靶点有白细胞介素-1β(interleukin-1β,IL-1β)、肿瘤坏死因子(tumor necrosis factor,TNF)及IL-6,涉及TNF信号通路、IL-17信号通路和NOD样受体信号通路等。大鼠踝关节注射MSU晶体后明显肿胀(P<0.01),SUA及CRP显著升高(P<0.05、0.01),滑膜组织增生明显、结构紊乱,有大量炎症细胞浸润,NOD样受体热蛋白结构域相关蛋白3(NOD-like receptor thermal protein domain associated protein 3,NLRP3)、NIMA相关蛋白激酶7(NIMA-related kinases 7,NEK7)、凋亡相关斑点样蛋白(apoptosis-associated speck-like protein containing a CARD,ASC)、半胱氨酸天冬氨酸蛋白酶-1(cystein-asparate protease-1,Caspase-1)、消皮素D(gasdermin D,GSDMD)、IL-18、IL-1β、IL-6及TNF-α表达水平明显升高(P<0.01);秋水仙碱或金藤清痹颗粒治疗后,有效缓解踝关节肿胀(P<0.05、0.01),SUA及CRP均显著降低(P<0.05、0.01),关节滑膜增生、炎症细胞浸润均得到改善,同时显著抑制IL-1β、TNF-α及IL-6等靶点和NOD样受体信号通路的表达(P<0.05、0.01)。结论 金藤清痹颗粒对AGA大鼠具有明显的保护作用,其机制可能与抑制NOD样受体信号通路的异常激活,降低炎症因子水平,改善关节滑膜增生、炎症细胞浸润有关。 相似文献
83.
目的;探讨手术治疗胸椎结核的更好方法。方法;自1990年以来,对21例胸椎结核导致椎柱不稳的患者,应用病灶清除,哈氏棒内固定,椎间及椎板植骨的手术方法。本组平均33.2岁。胸7椎体6例,胸8椎体8例,胸10椎体7例,椎体压缩〈1/2椎体高度13例,〉1/2椎体高度8例,并不全瘫14例。手术中先行病灶清除,然后哈氏棒内固一,撑开后再次清除病灶,取肋骨和髂骨行椎间及椎板上植骨。术后化疗12~15月。结 相似文献
84.
血府逐瘀汤对乳鼠心肌细胞缺血再灌注损伤的影响 总被引:4,自引:0,他引:4
目的为探讨血府逐瘀汤对乳鼠心肌细胞缺血再灌注损伤的影响。方法应用培养的乳鼠心肌细胞造成缺血再灌注损伤的动物模型,观察心肌细胞中超氧化物岐化酶(SOD)的水平,推断细胞内活性氧的生成量;观察培养液中乳酸脱氢酶(LDH)活性改变以判断细胞损伤情况;并进行DNA琼脂糖凝胶电泳及末端脱氧核苷酸介导的脱氧尿苷三磷酸缺口末端标记法(TUNEL),以判断细胞死亡类型及程度。结果血府逐瘀汤可显著升高缺血再灌注时SOD的水平,显著降低LDH的水平。DNA电泳图谱表明:血府逐瘀汤可使DNA的拖尾基本消失;TUNEL显示血府逐瘀汤可显著减少缺血再灌注所致的心肌细胞死亡。结论血府逐瘀汤有保护缺血再灌注时心肌细胞免于死亡之功效。 相似文献
85.
The peroral pneumocolon examination 总被引:3,自引:0,他引:3
86.
摘要:目的 探讨新疆乌鲁木齐市维吾尔族人群成人支气管哮喘的影响因素。方法 本研究采用成组匹配病例对照研究方法,病例组为新疆医科大学第一附属医院呼吸内科在2014年1-12月确诊的维吾尔族支气管哮喘成人患者(n=120例),对照组为同期体检中心健康维吾尔族体检者(n=126例),两组在年龄、性别相匹配。采用问卷调查的方法收集相关暴露资料,并采用单因素分析及多因素非条件Logistic回归模型分析成人支气管哮喘影响因素。结果 多因素Logistic回归分析显示,吸烟(OR=1.88,95% CI:1.28~2.96)、家族支气管哮喘史(OR=6.20,95% CI:2.10~18.31)、家中铺有纯毛地毯数量多(OR=1.87,95% CI:1.18~2.95),睡眠质量(OR=1.46,95% CI:1.22~1.75),患慢性支气管炎(OR=13.43,95% CI:6.65~25.34)及过敏性鼻炎(OR=6.27,95% CI:3.63~10.81)是维吾尔族成人支气管哮喘的主要影响因素。结论 维吾尔族成人支气管哮喘是生活方式、环境及遗传等多种因素共同作用的结果,应加强对相关影响因素的预防及治疗,减少哮喘的发生,改善哮喘患者生活质量。 相似文献
87.
88.
Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane 总被引:22,自引:2,他引:22 下载免费PDF全文
The mechanism for consumption of terminal complement components and release of bound components from the surface of serum-resistant salmonella minnesota S218 was studied. Consumption of C8 and C9 by S218 occurred through interaction with C5b67 on the bacterial surface because C8 and C9 were consumed when added to S218 organisms previously incubated in C8-deficient serum and washed to remove all C5b67 on the bacterial surface because C8 and C9 were consumed when added to S218 organisms previously incubated in C8- deficient serum and washed to remove al but cell bound C5b67. Rapid release of (125)I C5 and (125)I C7 from the membrane of S218 was dependent on binding of C8 because (125)I C5 and (125)I C7 deposition in C8D serum was stable and was twofold higher in C8D than in PNHA, and addition of purified C8 or C8 and C9 to S218 previously incubated in C8D serum caused rapid release of (125)I C5 and (125)I C7 from the organism. Analysis by sucrose density gradient ultracentrifugation of the fluid phase from the reaction of S218 and 10 percent PNHS revealed a peak consistent with SC5b-9, in which the C9:C7 ratio was 3.3:1, but the NaDOC extracted bound C5b-9 complex sedimented as a broad peak with C9:C7 of less than 1.2:1. Progressive elution of C5b67 and C5b-9 from S218 but not serum-sensitive S. minnesota Re595 was observed with incubation in buffers of increasing ionic strength. Greater than 90 percent of the bound counts of (125)I C5 or (125)I C9 were released from S218 by incubation in 0.1 percent trypsin, but only 57 percent of (125)I C9 were released by treatment of Re595 with trypsin. These results are consistent with the concept that C5b-9 forms on the surface of the serum-sensitive S. minnesota S218 in normal human serum, but the formed complex is released and is not bactericidal for S218 because it fails to insert into hydrophobic outer membrane domains. 相似文献
89.
A perfluorocarbon blood substitute, Fluosol, is undergoing clinical trials as an adjunct to chemotherapy. The adverse effects associated with its administration have been postulated to result from complement activation. When gel electrophoresis and Western blotting of Fluosol are used after its incubation with serum, activated C3 and factors Bb and H are bound to the Fluosol particles in a time-dependent fashion, which suggests that complement activation with Fluosol, as does that with zymosan, occurs on the surface of the particles. Paradoxically, it is found, both by the measurement of Fluosol-bound C3d and by fluid-phase C5a, that lower concentrations of Fluosol cause greater amounts of complement activation, which suggests a complex interaction of activators and inhibitors that changes as the available surface area is decreased. Studies performed with bystander red cell-bound C3d demonstrated in vivo complement activation occurring in six patients receiving Fluosol as an adjunct to chemotherapy for colon cancer. In two patients, there was a marked increase in red cell-bound C3d after Fluosol infusion; these two patients also developed adverse reactions during Fluosol infusion. These studies suggest that the Fluosol surface plays a major role in the initiation and regulation of complement activation that is seen during Fluosol infusion. 相似文献
90.